CVRx (NASDAQ:CVRX – Get Free Report) and Nuwellis (NASDAQ:NUWE – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.
Volatility & Risk
CVRx has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.
Profitability
This table compares CVRx and Nuwellis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CVRx | -89.14% | -120.76% | -48.38% |
| Nuwellis | -214.90% | -32,351.83% | -249.08% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CVRx | 1 | 0 | 1 | 2 | 3.00 |
| Nuwellis | 1 | 0 | 0 | 0 | 1.00 |
CVRx presently has a consensus price target of $11.50, suggesting a potential upside of 130.92%. Given CVRx’s stronger consensus rating and higher possible upside, research analysts plainly believe CVRx is more favorable than Nuwellis.
Earnings and Valuation
This table compares CVRx and Nuwellis”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CVRx | $56.65 million | 2.33 | -$53.31 million | ($2.02) | -2.47 |
| Nuwellis | $8.27 million | 0.04 | -$17.52 million | ($64.02) | 0.00 |
Nuwellis has lower revenue, but higher earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
75.3% of CVRx shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 18.9% of CVRx shares are held by insiders. Comparatively, 1.6% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
CVRx beats Nuwellis on 13 of the 15 factors compared between the two stocks.
About CVRx
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
About Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.
